Many quinolones have been approved by various regulatory agencies worldwide and some have been withdrawn after widespread use revealed unforeseen toxicities. Examples of this include temafl oxacin, which was found to be associated with hypoglycemia and hemolytic-uremic syndrome and trovafl oxacin, found to be associated with severe hepatotoxicity (2, 3). Although serious adverse events following quinolone use are relatively rare, some that have been associated with these drugs include prolongation of the QTc interval which can predispose to serious, life-threatening arrhythmias, rash, seizure, glucose intolerance and, as already mentioned, hepatotoxicity (4).
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Lescher GY, Froelich ED, Gruet MD, Bailey JH, Brundage RP. 1,8 naphthyridine derivatives: a new class of chemotherapy agents. J Med Pharm Chem 1962;5:1063–1068
Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. Clin Infect Dis 1994;18:946–950
Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002;127:269–277
Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003;51(Suppl S1): 21–27
Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol 1999;2:504–508
Markham PN, Neyfakh AA. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996;40:2673–2674
Markham PN. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine. Antimicrob Agents Chemother 1999;43:988–989
Lomovskaya O, Lee A, Hoshino K, et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43:1340–1346
Poole K. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother 2000;44:2595–2599
Jacobs MR. Fluoroquinolones as chemotherapeutic agents against mycobacterial infections. Curr Pharm Des 2004;10:3213–3220
Niedermann MS. Principles of appropriate antibiotic use. Int J Antimicrob Agents 2005;26(Suppl 3):S170–S175
Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998;351:797–799
Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: and enzyme that introduces negative superhelical turns into DNA. Proc Natl Acad Sci USA 1976;73:3872–3876
Drlica K, Zhao X. DNA gyrase, topoisomerase I V, and the 4-quinolones. Microbiol Mol Biol Rev 1997;61:377–392
Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa JI. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 1977; 74:4772–4776
Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H. New topoisomerase essential for chromosome segregation in E. coli. Cell 1990;63:393–404
Ullsperger C, Cozzarelli N. Contrasting enzymatic activities of topoisomerase IV and DNA gyrase from Escherichia coli. J Biol Chem 1996;271:31549–31555
Peng H, Marians KJ. The interaction of Escherichia coli topoi-somerase IV with DNA. J Biol Chem 1995;270:25286–25290
Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 1995;92:11801–11805
Hoshino K, Kitamura A, Morrissey I, Sato K, Kato J, Ikeda H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994;38:2623–2627
Khodursky AB, Cozzarelli NR. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem 1998;273:27668–27677
Kampranis SC, Maxwell A. Conformational changes in DNA gyrase revealed by limited proteolysis. J Biol Chem 1998;273: 22606–22614
Krueger S, Zaccai G, Wlodawer A, et al. Neutron and light-scattering studies of DNA gyrase and its complex with DNA. J Mol Biol 1990;211:211–220
Marians KJ, Hiasa H. Mechanism of quinolone action. A drug-induced structural perturbation of the DNA preceded strand cleavage by topoisomerase IV. J Biol Chem 1997;272:9401–9409
Hiasa H, Yousef DO, Marians KJ. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex. J Biol Chem 1996;271:26424–26429
Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41(Suppl 2):S120–S126
Yamagishi J, Kojima T, Oyamada Y, et al. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996;40:1157–1163
Schmitz F-J, Higgins PG, Mayer S, Fluit AC. Activity of qui-nolones against gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 2002;21: 647–659
Blanche F, Cameron B, Bernard FX, et al. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoi-somerases. Antimicrob Agents Chemother 1996;40:2714–2720
Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003;51:1109–1117
Hooper DC. Mechanisms of quinolone resistance. In: Hooper DC, Rubenstein E, eds. Quinolone Antimicrobial Agents. Washington, DC: American Society for Microbiology, 2003, pp. 41–67
Horowitz DS, Wang JC. Mapping the active site tyrosine of Escherichia coli DNA gyrase. J Biol Chem 1987;262:5339–5344
Chapman JS, Georgopapadokou NH. Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother 1988;32:438–442
Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003;67:593–656
Cohen SP, Hooper DC, Wolfson JS, Souza KS, McMurry LM, Levy SB. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother 1988;32: 1187–1191
Wiedemann B, Heisig P. Mechanisms of quinolone resistance. Infection 1994;22(Suppl 2):S73–S79
Alekshun MN, Levy SB. Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon. Antimicrob Agents Chemother 1997;41:2067–2075
Chou JH, Greenberg JT, Demple B. Posttranscriptional repression of Escherichia coli OmpF protein in response to redox stress: positive control of the micF antisense RNA by the soxRS locus. J Bacteriol 1993;175:1026–1031
Yoshimura F, Nikaido H. Permeability of Pseudomonas aerugi-nosa outer membrane to hydrophilic solutes. J Bacteriol 1982;152: 636–642
Roberts MC. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett 2005;245:195–203
Poole K. Efflux-mediated resistance to fluoroquinolones in gram- negative bacteria. Antimicrob Agents Chemother 2000;44: 2233–2241
Okusu H, Ma D, Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol 1996;178:306–308
Zgurskaya HI, Nikaido H. Cross-linked complex between oli-gomeric periplasmic lipoprotein AcrA and the inner-membrane-associated multidrug efflux pump AcrB from Escherichia coli. J Bacteriol 2000;182:4264–4267
Alekshun MN, Levy SB. The mar regulon: multiple resistance to antibiotics and other toxic chemicals. Trends Microbiol 1999;7:410–413
Murakami S, Nakashima R, Yamashita E, Yamaguchi A. Crystal structure of bacterial multidrug transporter AcrB. Nature 2002;419:587–593
Elkins CA, Nikaido H. Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops. J Bacteriol 2002;184:6490–6498
Li X-Z, Livermore DM, Nikaido H. Role of efflux pumps in intrinsic resistance of Pseudomonas aeruginosa: resistance to tet-racycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 1994;38:1732–1741
Alonso A, Martinez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas mal-tophilia. Antimicrob Agents Chemother 2000;45:1879–1881
Morita Y, Kodama K, Shiota S, et al. NorM, a putative multid-rug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother 1998;42: 1778–1782
Miyamae S, Ueda O, Yoshimura F, Hwang J, Tanaka Y, Nikaido H. A MATE family multidrug efflux transporter pumps out fluoro-quinolones in Bacteriodes thetaiotaomicron. Antimicrob Agents Chemother 2001;45:3341–3346
Colmer JA, Fralick JA, Hamood AN. Isolation and characterization of a putative multidrug efflux pump from Vibrio cholerae. Mol Microbiol 1998;27:63–72
Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002;99:5638–5642
Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother 2005;49: 118–125
Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother 2005;49: 3050–3052
Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother 2003;47:2242–2248
Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother 2004;48:1295–1299
Robicsek A, Sahm DF, Strahilevitz J, Jacoby GA, Hooper DC. Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob Agents Chemother 2005;49: 3001–3003
Jacoby GA, Walsh KE, Mills DM, et al. qnrB, another plas-mid-mediated gene for quinolone resistance. Antimicrob Agents Chemother 2006;50:1178–1182
Martens R, Wetzstein H-G, Zadrazil F, Capelari M, Hoffman P, Schmeer N. Degradation of the fluoroquinolone enrofloxacin by wood-rotting fungi. Appl Environ Microbiol 1996;62:4206–4209
Wetzstein H-G, Stadler M, Tichy H-V, Dalhoff A, Karl W. Degradation of ciprofloxacin by basidiomyectes and identification of metabolites generated by the brown rot fungus Gloeophyllum striatum. Appl Environ Microbiol 1999;65:1556–1563
Robicsek A, Strahilevitz J, Jacoby GA, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006;12:83–88
Ng E Y, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1996;40:1881–1888
Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother 1993;37:128–129
Yu J-L, Grinius L, Hooper DC. NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol 2002;184:1370–1377
Hsieh P-C, Siegel SA, Rogers B, Davis D, Lewis K. Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. Proc Natl Acad Sci USA 1998;95:6602–6606
Kaatz GW, Seo SM, O'Brien L, Wahiduzzaman M, Foster TJ. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother 2000;44:1404–1406
Yoshida H, Bogaki M, Nakamura S, Ubukata K, Konno M. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol 1990;172:6942–6949
Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroqui-nolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1993;37:1086–1094
Kaatz GW, Thyagarajan RV, Seo SM. Effect of promoter region mutations and mgrA overexpression on transcription of norA, which encodes a Staphylococcus aureus multidrug efflux transporter. Antimicrob Agents Chemother 2005;49:161–169
Ingavale SS, Van Wamel W, Cheung AL. Characterization of RAT, and autolysis regulator in Staphylococcus aureus. Mol Microbiol 2003;48:1451–1466
Luong TT, Newell SW, Lee C Y. mgr, a novel global regulator in Staphylococcus aureus. J Bacteriol 2003;185:3703–3710
Ingavale S, Van Wamel W, Luong TT, Lee CY, Cheung AL. Rat/ MgrA, a regulator of autolysis, is a regulator of virulence genes in Staphylococcus aureus. Infect Immun 2005;73:1423–1431
Luong TT, Dunman PM, Murphy E, Projan SJ, Lee CY. Transcription profiling of the mgrA regulon in Staphylococcus aureus. J Bacteriol 2006;188:1899–1910
Truong-Bolduc Q-C, Dunman PM, Strahilevitz J, Projan SJ, Hooper DC. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol 2005;187:2395–2405
Truong-Bolduc Q-C, Strahilevitz J, Hooper DC. NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:1104–1107
Huang J, O'Toole P, Shen W. Novel chromosomally-encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:909–917
Yamada Y, Shiota S, Mizushima T, Kuroda T, Tsuchiya T. Functional gene cloning and characterization of MdeA, a multi-drug efflux pump from Staphylococcus aureus. Biol Pharm Bull 2006;29:801–804
Neyfakh AA, Bidnenko VE, Chen LB. Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. Proc Natl Acad Sci USA 1991;88:4781–4785
Neyfakh AA. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homologue of the Staphylococcus aureus NorA protein. Antimicrob Agents Chemother 1992;36:484–485
Ahmed M, Borsch CM, Taylor SS, Vazquez-Laslop N, Neyfakh AA. A protein that activates expression of a multidrug efflux trans- porter upon binding the transporter substrates. J Biol Chem 1994;269:28506–28513
Zheleznova EE, Markham PN, Neyfakh AA, Brennan RG. Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter. Cell 1999;96:353–362
Ahmed M, Lyass L, Markham PN, Taylor SS, Vazquez-Laslop N, Neyfakh AA. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated. J Bacteriol 1995;177:3904–3910
Baranova NN, Danchin A, Neyfakh AA. Mta, a global MerR-type regulator of the Bacillus subtilis multidrug-efflux transporters. Mol Microbiol 1999;31:1549–1559
Ohki R, Murata M. bmr3, a third multidrug transporter gene of Bacillus subtilis. J Bacteriol 1997;179:1423–1427
Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:187–189
Piddock LJV, Johnson MM, Simjee S, Pumbwe L. Expression of efflux pump geme pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2002;46:808–812
Jonas BM, Murray BE, Weinstock GM. Characterization of emeA, a norA homologue and multidrug resistance efflux pump, in Enterococcus faecalis. Antimicrob Agents Chemother 2001;45:3574–3579
Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem J 2003;376:313–338
Dridi L, Tankovic J, Petit JC. CdeA of Clostridium difficile, a new multidrug efflux transporter of the MATE family. Microb Drug Resist 2004;10:191–196
Kaatz GW, McAleese F, Seo SM. Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob Agents Chemother 2005;49:1857–1864
McAleese F, Petersen P, Ruzin A, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005;49:1865–1871
Kaatz GW, DeMarco CE, Seo SM. MepR, a repressor of the Staphylococcus aureus MATE family multidrug efflux pump MepA, is a substrate-responsive regulatory protein. Antimicrob Agents Chemother 2006;50:1276–1281
Akhaddar A, El Mostarchid B, Gazzaz M, Boucetta M. Cerebellar abscess due to Lactococcus lactis. A new pathogen. Acta Neurochir 2002;144:305–306
Poelarends GJ, Mazurkiewicz P, Konings WN. Multidrug transporters and antibiotic resistance in Lactococcus lactis. Biochim Biophys Acta 2002;1555:1–7
Kaatz GW. Bacterial efflux pump inhibition. Curr Opin Investig Drugs 2005;6:191–198
Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45:105–116
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Moudgal, V.V., Kaatz, G.W. (2009). Fluoroquinolone Resistance in Bacteria. In: Mayers, D.L. (eds) Antimicrobial Drug Resistance. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-59745-180-2_16
Download citation
DOI: https://doi.org/10.1007/978-1-59745-180-2_16
Publisher Name: Humana Press
Print ISBN: 978-1-60327-592-7
Online ISBN: 978-1-59745-180-2
eBook Packages: MedicineMedicine (R0)